Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.
about
Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and Beta-lactamsMaraviroc: a review of its use in HIV infection and beyondA review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practiceAssessment of the pharmacokinetics of co-administered maraviroc and raltegravirDrug interactions with new and investigational antiretrovirals.Etravirine (TMC-125): The evidence for its place in the treatment of HIV-1 infectionCYP3A5 genotype impacts maraviroc concentrations in healthy volunteers.Maraviroc, a CCR5 coreceptor antagonist that blocks entry of human immunodeficiency virus type 1.Maraviroc for previously treated patients with R5 HIV-1 infectionPharmacokinetic interactions of maraviroc with darunavir-ritonavir, etravirine, and etravirine-darunavir-ritonavir in healthy volunteers: results of two drug interaction trials.Clinical use of CCR5 inhibitors in HIV and beyondSchisandrol B protects against acetaminophen-induced hepatotoxicity by inhibition of CYP-mediated bioactivation and regulation of liver regeneration.Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteersTowards a Best Practice Approach in PBPK Modeling: Case Example of Developing a Unified Efavirenz Model Accounting for Induction of CYPs 3A4 and 2B6Pharmacokinetic interaction between maraviroc and fosamprenavir-ritonavir: an open-label, fixed-sequence study in healthy subjects.Antiretroviral drug interactions: overview of interactions involving new and investigational agents and the role of therapeutic drug monitoring for management.Pharmacotherapy of HIV-1 Infection: Focus on CCR5 Antagonist Maraviroc.New antiretroviral drugs: a review of the efficacy, safety, pharmacokinetics, and resistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir.Treatment of HIV infection with the CCR5 antagonist maraviroc.Clinical utility of maraviroc.Drug safety evaluation of maraviroc for the treatment of HIV infection.Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug-drug interactions with rifamycins.Neurotoxicity in the Post-HAART Era: Caution for the Antiretroviral Therapeutics.Use of a physiologically based pharmacokinetic model to simulate drug-drug interactions between antineoplastic and antiretroviral drugs.A novel probe drug interaction study to investigate the effect of selected antiretroviral combinations on the pharmacokinetics of a single oral dose of maraviroc in HIV-positive subjects.Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes.Preclinical discovery and development of maraviroc for the treatment of HIV.Effects of etravirine alone and with ritonavir-boosted protease inhibitors on the pharmacokinetics of dolutegravir.Clinical relevance of CYP3A5 genotype on maraviroc exposures.Pharmacokinetics, safety, and tolerability of maraviroc in HIV-negative subjects with impaired renal function.Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration.Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach.Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective.
P2860
Q24631021-0D7E0E77-0490-4959-B1D5-EE7C21958EF3Q26778504-36AE9AC9-ED05-40EF-B73B-AA1689626658Q27692040-59BF393E-46B4-4269-8872-912BA7BDCC6FQ33696575-13F20552-1BCF-4F61-9AB4-5654B75B7F03Q33801821-BB669173-66D0-481F-B60A-F472CF43E132Q33973857-101B5579-BC5B-4BFD-B1A0-376AF9E72045Q34360012-54CE319F-BA75-40CF-9292-6AFB0ADFAAE6Q34604941-CE8A159C-B6B5-44E0-8C76-95DD502BC2B7Q34806062-7B746E4D-9B7F-45C1-8D6F-9A1484AC19C6Q34932654-81DEC1F2-86A9-487B-808B-822BA59E7B5FQ35018145-0131144D-685B-44ED-B1EC-97AA0BD157F3Q35102625-B4DDA985-56BA-4AA9-9371-51958A15BD14Q36558221-E7BB5536-2391-4619-A07A-BC2443CEFF07Q37126489-1DF6ED20-24EE-4312-9C3C-9312E240E11AQ37335653-DEB712D3-7F1D-4793-9FB4-3DE3834D0B01Q37378110-8F6D27EF-EF90-4F83-AE5C-7470E6E6D4D8Q37421895-55F9B9B9-A3F4-4BC8-A209-FA119A967F50Q37579219-140A8B0C-1ED2-4404-B93C-ABDF2420D508Q37733565-DD7C3EB7-9F62-48FA-B089-A358757E22D7Q37877242-A9CD55B5-D87F-482E-BC19-D61E1A2BEBC7Q37961188-287F370C-8080-4150-A423-2914A8845E6BQ38207924-42F8D272-522D-4FA8-9871-290CD5C16F4BQ38882614-0F87C2FF-3867-4205-83B7-35D0C588A495Q39080596-5E8A00F8-C0E8-41E1-9F26-760DDA1A9858Q39366281-47C22676-937C-4BD3-B016-187E8DCD004FQ39418438-046A2D72-076C-465E-88B7-39B99EA967E4Q39556338-3C315A3C-60C7-40E6-88A4-96AE29DE5B11Q41861540-3018DCE1-744F-48DD-808E-7471F73A6B33Q42592141-12FAA019-64CE-40DD-ADA1-462C80FB9B4DQ42607941-8AE0D317-92D8-4107-9F6B-185749A04F5EQ43108044-F9BC1D7A-05BF-4750-A6BF-89CCFFD56C2FQ48500206-EF362484-7D22-478F-AF95-1ABE331885D1Q50120162-AE4331E3-50EE-4C75-B1AB-80429EFFC730
P2860
Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.
description
2008 nî lūn-bûn
@nan
2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Effects of CYP3A4 inducers wit ...... raviroc in healthy volunteers.
@ast
Effects of CYP3A4 inducers wit ...... raviroc in healthy volunteers.
@en
Effects of CYP3A4 inducers wit ...... raviroc in healthy volunteers.
@nl
type
label
Effects of CYP3A4 inducers wit ...... raviroc in healthy volunteers.
@ast
Effects of CYP3A4 inducers wit ...... raviroc in healthy volunteers.
@en
Effects of CYP3A4 inducers wit ...... raviroc in healthy volunteers.
@nl
prefLabel
Effects of CYP3A4 inducers wit ...... raviroc in healthy volunteers.
@ast
Effects of CYP3A4 inducers wit ...... raviroc in healthy volunteers.
@en
Effects of CYP3A4 inducers wit ...... raviroc in healthy volunteers.
@nl
P2093
P2860
P1476
Effects of CYP3A4 inducers wit ...... raviroc in healthy volunteers.
@en
P2093
Caroline E Ridgway
Gary J Muirhead
Lyndsey A Whitlock
Samantha Abel
Timothy M Jenkins
P2860
P356
10.1111/J.1365-2125.2008.03134.X
P407
P478
65 Suppl 1
P577
2008-04-01T00:00:00Z